MRNA vs RYAN · rev $1.94B vs P/E 43, rev $2.46B
Moderna Inc (MRNA) versus Ryan Specialty Group Holdings Inc (RYAN) — a side-by-side from cached financials, not a winner call.
Moderna Inc (MRNA) is a biotechnology company listed on NASDAQ. It is led by Stephane Bancel.
Ryan Specialty Group Holdings Inc (RYAN) is a insurance - specialty company listed on NYSE.
Latest reported MRNA revenue for 2025-12-31 was $1.94B. Net income was -$2.82B. Revenue was down 39.9% from 2024-12-31 to 2025-12-31. MRNA currently screens at market cap $24.52B.
Latest reported RYAN revenue for 2024-12-31 was $2.46B. Net income was $229.9M. Revenue was up 21.2% from 2023-12-31 to 2024-12-31. RYAN currently screens at market cap $9.33B and trailing P/E 43.1.
MRNA currently screens at market cap $24.52B. RYAN currently screens at market cap $9.33B and trailing P/E 43.1.
Not investment advice. Open the MRNA and RYAN stock pages for the full models.
Not investment advice.